Introduction
Valproic acid (2-propylpentanoic acid) has been successfully used as an anticonvulsant agent for over 30 years. The drug is primarily indicated for the treatment of various forms of epilepsy. The anticonvulsant efficacy of valproic acid is highly variable and dependent upon the type and severity of seizure and an individual's pharmacokinetic parameters. The minimum effective serum concentration for optimal seizure control is approximately 50 rag/L, and seizure control tends to improve as concentration increases over the range of 50 to 100 mg/L ~ Autho~ to whom all correspondence should be addressed: Department of Pathology, Medical
College of Virginia, Box 98-0165 MCV Statioo, Virginia Commcmwealth University, Richmond, VA 2329~O165.
* Current address: Medical Examiner Maricopa County, 120 South Sixth Avenue, Phoenix, AZ 85003, (1, 2) . Therapeutic doses range from 200 to 2500 mg daily. Adverse reactions associated with valproic acid therapy include mild ataxia, nausea, vomiting, and tremor (3, 4) . Fatal pancreatitis (5--7) and hepatotoxicity (8) (9) (10) , particularly in children, have developed during valproic acid therapy. Acute intoxication attributable to massive valproic acid overdose is uncommon and may be successfully treated when discovered (11) (12) (13) (14) . Central nervous system toxicity with symptoms varying from drowsiness to coma and cerebral edema is the most frequent effect of overdose. Respiratory failure has been observed in all fatal cases (13) . Fatal overdose is rare, and only limited data concerning toxic and fatal blood and tissue concentrations are available in the published literature (15) (16) (17) (18) (19) (20) (21) (22) (23) .
We report a case of fatal suicidal valproic acid overdose. Valproic acid concentrations were determined in body tissues and fluids by quantitative immunoassay and gas-liquid chromatography (GLC) following both direct extraction and the method of standards addition. Qualitative identification of vaiproic acid as its methylated derivative was by ion-trap gas chromatography-mass spectrometry (GC-MS). Case findings were compared to previous fatalities.
Case History
The deceased was a 28-year-old Caucasian male found dead in his bedroom. He had a history of epilepsy and had recently experienced several business and personal failures. A prescription for 120 500-mg valproic acid tablets, one to be taken twice daily, had been filled the day prior to his death. Only 17 tablets were recovered at the scene. A suicide note was also found next to the body. With the exception of generalized visceral congestion and acute pulmonary and cerebral edema, gross pathology and histopathological findings were unremarkable. Body fluids and tissues were collected and sent for toxicological analysis.
Toxicological Analysis

Sample preparation
Blood, bile, and vitreous humor samples were diluted with an equal quantity of distilled water before analysis. One-gram samples of brain, liver, kidney, and heart were diluted with 4.0 mL of distilled water and mixed in a small ground glass homogenizer. Aliquots of these homogenates were then analyzed by the methods described here.
Immunoassay
All reagents necessary for fluorescence polarization immunoassay (FPIA) were purchased from Abbott Laboratories (Abbott Park, IL). The FPIA valproic acid assays were performed in an Abbott TDx analyzer with 3.03 version software. The calibration curve for the assay was constructed with six calibrator solutions supplied with the assay consisting of valproic acid concentrations of 0, 12.5, 25, 50, 100, and 150 mg/L. FPIA controls with target values of 37.5, 72.5, and 124.5 mg/L vaiproic acid were obtained from Abbott Laboratories. All immunoassay reagents were stored refrigerated at 1~
GLC reagents
HCl (1N) was prepared by diluting 86 mL concentrated hydrochloric acid to 1 L with distilled water. Methanol, chloroform, and hydrochloric acid were all ACS grade or better.
GLC standards
Stock valproic acid standard, 1000 mg/L, was prepared by dissolving 115.2 mg sodium valproate (propylpentanoic acid, Sigma Chemical Co., St. Louis, MO) in 100 mL methanol. A calibration curve was prepared using 0-200 mg/L concentrations in drug-free serum. Stock Internal standard, 7.0 mglL, was prepared by diluting 1.0 mL Cyclohexane carboxylic acid (Aldrich Chemical Co., Milwaukee, WI) to 150 mL with methanol. This compound is a semi-solid at room temperature and was placed in a 37~ water bath until melted before diluting. Working internal standard solution was prepared by diluting the stock solution 1:40 with methanol. Control serums with target values of 25 mg/L (Quality Assurance Services, Augusta, GA), 60 mg/L (chemTRAK| Medical Analysis Systems, Inc., Carmarillo, CA), and 120 mglL (Lyphocheck | Bio-Rad Laboratories, Hercules, CA) valproic acid were analyzed with each batch of samples.
Direct extraction procedure
Quantitative GLC analysis of valproic acid was based upon the method of Wohler and Poklis (24) . Aliquots of 200 ~L working internal standard and 200 ]~L of calibrator, control, or sample were pipetted into separate 12-ram x 75-mm test tubes and mixed lightly in hand. One-hundred microliters IN HCI and 500 pL chloroform were added to each tube. The mixture was then vortex mixed for 15 s and centrifuged at 3400 rpm for 5 min. One microliter of the lower chloroform layer was injected into the GC. Valproic acid serum concentrations were calculated from a linear regression of the calibrator responses based on peak-height ratio (peak height of valproic acid to that of the internal standard). The presented method for valproic acid in
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mg/L, and it was linear up to 6000 mg/L (24).
Standard addition procedure
To three 200-mL aliquots of sample homogenate were added valproic acid calibrator to produce separate aliquots with additional valproic acid concentrations of 50, 100, and 150 mg/L. The aliquots were vortex mixed, allowed to stand for 4 h, and than extracted as described here under the direct extraction procedure. The valproic acid concentration in the sample was determined by the linear regression equation: y (total concentration determined against internal standard) = x (concentration added to aliquot) + b, where b is the actual concentration in the aliquot. All regression equations for each specimen yielded slopes of 1 and r 2 values of 1.
GLC instrumentation
Analyses were performed on a Shimadzu GC-14 GC equipped with a flame ionization detector. The detector response was recorded and integrated on a Hewlett Packard 3395 integrator. Chromatography was performed isothermally at 140~ on a hydrogen, 20 mL/min; and air, 300 mL/min. Under these conditions, the retention times were as follows: valproic acid, 3.0 min and internal standard, 5.4 min. The relative retention time (RRT) of valproic acid to the internal standard was 0.56.
GC-MS
Following direct extraction as described, chloroform extracts were evaporated, dissolved in 100 pL of ethyl acetate, methylated with 50 laL of trimethylanilinium hydroxide (Pierce, Rockford, IL), and injected into the GC-MS. The GC was a Varian Star model 3400Cx with a split/splitless injection port connected to a Varian Saturn model 3 ion-trap (IT) MS with Saturn software version 5.2 to control the operation of the GC and IT. The GC oven program was as follows: initial temperature, 60~ initial time, 1.0 rain; rate, 15~ final temperature, 300~ and final time, 3.0 rain. The injection port temperature was 170~ and the transfer line temperature was 280~ The column was a DB-5rns capillary column (30 m x 0.25 mm i.d., 0.25-pro film thickness). The IT was operated in the full scan mode. Tissue extract spectra were compared with that of unextracted derivatized valproic acid. The methylvalproate derivative yielded the following major fragments and relative abundances: 87 (100%); 115 (50%); 55 (33%); 57 (30%); and molecular ion, 159 (30%) (Figure 1 ). 
Results and Discussion
The results of the toxicological analysis by the three different procedures are presented in Table I . The results between the procedures were in good agreement. Both diluted body fluids and tissue homogenates were easily analyzed by the FPIA immunoassay yielding comparable results to gas-liquid chromatography. The agreement between the direct extraction procedure and the method of standard additions demonstrates the lack of matrix effects and ease of direct extraction of valproic acid from tissue matrices.
Only eight cases of fatal valproic acid overdose have been reported in the literature (15) (16) (17) (18) (19) (20) (21) (22) (23) (23) and 800 mg/kg (22) have been reported in only two other cases. The findings in the presented case far exceed those observed in a patient receiving therapeutic doses (25) and are similar to those in a prior fatal overdose (22) (Table II) . The ratios of the valproic acid concentrations in the solid tissues to those of the blood ranged from 0.48 for the brain to 1.5 for the kidney. This is consistent with the relatively low apparent volume of distribution of valproic acid, 0.1 to 0.5 L/kg, which results from its extensive serum protein binding (> 90%) and ionization at physiological pH (> 90%) (1) .
The deceased had available to him a new prescription for 120 500-mg valproic acid tablets of which only 17 were found. Several older empty prescription vials for valproic acid were also recovered at the scene. This indicated ingestion of a dose of at least 51.5 g. As 15.1 g of valproic acid was recovered in the stomach contents, it was assumed that the absorbed dose was at least 36.4 g of valproate. The probable ingested dose was also determined by a pharmacokinetic-based estimate relating the decedent's weight (79 kg at the time of death), the measured valproate blood concentration (1.05 g/L), and the volume of distribution of valpmic acid (0.5 IJkg). The calculation yielded an absorbed dose of 41.5 g of valproate. Given that the decedent was routinely ingesting 1.0 g daily by prescription before his death, it can be assumed that he would have had at least several grams ofvalpmate in his body before the overdose. Therefore, the pharrnacokinetic estimate is approximately 39.5 g, which is in good agreement with the amount based upon the death scene investigation.
Conclusion
Based on the circumstances surrounding the presented death, unrernarkable pathology, and the high tissue concentrations and dose of valpmic acid ingested, the cause of death was attributed to an overdose of valproic acid. The manner of death was ruled suicide. Because of the relatively low apparent volume of distribution of valproic acid, tissue concentrations do not vary widely as compared with blood values and the drug may be reliably analyzed in tissue homogenates by direct extraction GLC or FPIA.
